These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 3992517)

  • 21. A study of the effects of venous occlusion on haemostatic variables in males and females.
    Datta S; Gaur S; Bhargava RP
    Indian J Physiol Pharmacol; 1982; 26(4):295-301. PubMed ID: 7152638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of venous occlusion and DDAVP injection on platelet aggregation and platelet cyclic AMP.
    Egberg N
    Thromb Res; 1980 Jul 1-15; 19(1-2):263-5. PubMed ID: 6255627
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of des-amino-D-arginine vasopressin (DDAVP) on plasma levels of platelet and endothelial cell release products.
    D'Angelo A; Capitanio A; Smith JB; Valsecchi C; Mannucci PM
    Thromb Haemost; 1983 Feb; 49(1):64-5. PubMed ID: 6687766
    [No Abstract]   [Full Text] [Related]  

  • 24. Desmopressin-induced improvement of abnormal coagulation in chronic liver disease.
    Agnelli G; Berrettini M; De Cunto M; Nenci GG
    Lancet; 1983 Mar; 1(8325):645. PubMed ID: 6131320
    [No Abstract]   [Full Text] [Related]  

  • 25. Blood fibrinolysis and the response to desmopressin in glomerulonephritis.
    Brommer EJ; Van den Wall Bake AW; Dooijewaard G; van Loon BJ; Emeis JJ; Weening JJ
    Thromb Haemost; 1994 Jan; 71(1):19-25. PubMed ID: 8165642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Disorders of the fibrinolytic capacity in patients with chronic kidney failure].
    Opatrný K; Cepelák V; Opatrný K; Dvorák J; Kott J; Sefrna F; Cepeláková H
    Cas Lek Cesk; 1988 Apr; 127(15):461-3. PubMed ID: 3378251
    [No Abstract]   [Full Text] [Related]  

  • 27. [The potentiation of adjuvant arthritis in rats by vasopressin and its V2 agonist].
    Igonina NA; Evseev VA; Kulikova OS
    Patol Fiziol Eksp Ter; 1999; (3):30-1. PubMed ID: 10498993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. On the correlation between local fibrinolytic activity in menstrual fluid and total blood loss during menstruation and effects of desmopressin.
    Edlund M; Blombäck M; He S
    Blood Coagul Fibrinolysis; 2003 Sep; 14(6):593-8. PubMed ID: 12960614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secretory response of the vessel wall to DDAVP and venous occlusion in von Willebrand's disease.
    Bykowska K; Letowska M; Sabliński J; Binder BR; Kopeć M; Lopaciuk S
    Acta Haematol Pol; 1994; 25(3):261-8. PubMed ID: 7992599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Masking of fibrinolytic response to stimulation by an inhibitor of tissue-type plasminogen activator in plasma.
    Brommer EJ; Verheijen JH; Chang GT; Rijken DC
    Thromb Haemost; 1984 Oct; 52(2):154-6. PubMed ID: 6441302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Experiences with intranasal and parenteral use of 1-desamino-8-D-arginine vasopressin (DDAVP). Use in a simple test of renal concentrating ability].
    Tuschy U; Szeszat S; Rindfleisch U
    Z Gesamte Inn Med; 1984 Jun; 39(11):265-8. PubMed ID: 6475171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 1-Desamino-8-D-arginine vasopressin (DDAVP) in patients with congenital nephrogenic diabetes insipidus.
    Brink HS; Derkx FH; Boomsma F; Brommer EJ; Schalekamp MA
    Neth J Med; 1993 Aug; 43(1-2):5-12. PubMed ID: 8232694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparative studies on fibrinolytic activity in healthy subjects and patients with arterial and venous vascular disorders].
    Scharrer I; Feigel U; Krebs H; Breddin K
    Verh Dtsch Ges Inn Med; 1975; 81():1150-2. PubMed ID: 1229421
    [No Abstract]   [Full Text] [Related]  

  • 34. Effects of lysine-vasopressin (LVP) and 1-deamino-8-D-arginine-vasopressin (dDAVP) upon electrical potential, short-circuit current and transepithelial D.C. resistance of the frog skin.
    Bakos P; Ponec J; Lichardus B
    Gen Physiol Biophys; 1984 Aug; 3(4):297-305. PubMed ID: 6094299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interaction of vasopressin and renal prostaglandins in the homozygous diabetes insipidus rat.
    Dunn MJ; Kinter LB; Beeuwkes R; Shier D; Greeley HP; Valtin H
    Adv Prostaglandin Thromboxane Res; 1980; 7():1009-13. PubMed ID: 7369014
    [No Abstract]   [Full Text] [Related]  

  • 36. Desamino-D-Arginine vasopressin induces fatty acid cyclooxygenase activity in the renal medulla of diabetes insipidus rats.
    Beck TR; Hassid A; Dunn MJ
    J Pharmacol Exp Ther; 1982 May; 221(2):269-74. PubMed ID: 6804621
    [No Abstract]   [Full Text] [Related]  

  • 37. Enhanced cardiovascular reactivity to desmopressin in water-restricted rats: facilitatory role of immunosuppression.
    Tyagi MG; Thomas M
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):619-24. PubMed ID: 10669908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physiologic and pharmacologic enhancement of fibrinolysis.
    Prowse CV; Cash JD
    Semin Thromb Hemost; 1984 Jan; 10(1):51-60. PubMed ID: 6367048
    [No Abstract]   [Full Text] [Related]  

  • 39. Desmopressin stimulates the expression of P-selectin on human platelets in vitro.
    Wun T; Paglieroni TG; Lachant NA
    J Lab Clin Med; 1995 Oct; 126(4):401-9. PubMed ID: 7561450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New knowledge in Von Willebrand-Jürgens syndrome].
    Niessner H
    Acta Med Austriaca Suppl; 1982; 25():44-50. PubMed ID: 6982581
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.